netFormulary Harrogate & Rural District Formulary NHS
Harrogate & District NHS Foundation Trust
Harrogate & Rural District Clinical Commissioning Group
 
 
 Search
 Formulary Chapter 10: Musculoskeletal and joint diseases - Full Chapter
10.01.01  Expand sub section  Non-steroidal anti-inflammatory drugs
Naproxen
View adult BNF View SPC online View childrens BNF
First Choice Tablets 250mg

Switched to HDFT NSAID of choice November 2012 due to increased CV risk with diclofenac 
Ibuprofen
View adult BNF View SPC online View childrens BNF
Formulary Tablets 200mg, 400mg
Liquid 100mg/5ml
Gel 5% (50g) 
   
Diclofenac Sodium
View adult BNF View SPC online View childrens BNF
Formulary Tablets EC 25mg, 50mg
MR tablets 75mg, 100mg
Dispersible tablets 50mg
Suppositories 12.5mg, 50mg, 100mg
Gel 1% 
   
Diclofenac Sodium (Voltarol)
View adult BNF View SPC online View childrens BNF
Formulary Injection 75mg/3ml 
   
Indometacin
View adult BNF View SPC online View childrens BNF
Formulary Capsules 25mg, 50mg
MR tablets 75mg 
   
Mefenamic Acid
View adult BNF View SPC online View childrens BNF
Formulary Tablets 500mg 
   
Celecoxib (Celebrex)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted Capsules 100mg

Initiation on the advice of a Consultant Rheumatologist only 
   
Etoricoxib (Arcoxia)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted Tablets 30mg, 60mg, 90mg

Initiation on the advice of a Consultant Rheumatologist only 
   
10.01.01  Expand sub section  Aspirin
 ....
 Non Formulary Items
Acelofenac  (Preservex)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Acemetacin  (Emflex)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Azapropazone  (Rheumox)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Celecoxib  (Onsenal®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Dexibuprofen  (Seractil)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Dexketoprofen  (Keral)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Diclofenac Sodium with Misoprostol  (Arthrotec 50 and 75)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Etodolac

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Fenbufen

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Fenoprofen  (Fenopron)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Flurbiprofen

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Flurbiprofen  (Froben SR)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Hyaluronic acid  (Durolane )

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Red
Approved by HaRD Area Prescribing Committee January 2014 for one patient. Further requests to be submitted on an individual patient basis.
 
Ibuprofen  (Brufen Retard)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Indometacin  (Indometacin MR)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Ketoprofen

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Ketoprofen  (Axorid®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Ketoprofen  (Oruvail MR)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Lumiracoxib  (Prexige)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Meloxicam

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Nabumetone

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Naproxen with Misoprostol  (Napratec)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Piroxicam

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Sulindac

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Tenoxicam  (Mobiflex)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Tiaprofenic Acid

View adult BNF View SPC online View childrens BNF
Non Formulary
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Amber

Medicines which are suitable to be prescribed in primary care only after specialist recommendation. Ongoing prescribing by primary care includes titration of dose and assessment of efficacy. There is no need for ongoing monitoring other than for general adverse effects as listed in the BNF & SPC.  

Amber Shared Care

Medicines which are suitable to be prescribed in primary care only after specialist recommendation only under a shared care protocol once the patient has been stabilised. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must be approved by the Harrogate & Rurual District Area Prescribing Committee (HaRD APC).   

Black

Medicines which the Harrogate & Rural District Area Prescribing Committee (HaRD APC) has reviewed and does not recommend for use at present based on a review of clinical and/or cost effectiveness data.   

Green

Medicines suitable for routine use and can be prescribed within primary care within their licensed indication in accordance with nationally recognised formularies e.g. BNF, BNF for Children, Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing.  

Grey

Medicines which the Harrogate & Rural District Area Prescribing Committee (HaRD APC) have not yet reviewed.   

Red

Medicines for hospital use only. The responsibility for initiation and monitoring treatment should rest with an appropriate hospital clinician. The drug should be supplied by the hospital for the duration of the treatment course. Primary care prescriber initiation or continuation of treatemnt is not recommended.  

netFormulary